Please Note: All session times for the AACR Virtual Meeting: Precision Medicine Strategies to Improve Therapy of DLBCL are U.S. Eastern Standard Time (EST).

Thursday, September 30, 2021

• Session 1: Where Are We Now with DLBCL Therapy?
• Session 2: DLBCL Heterogeneity: Beyond Cell of Origin

Friday, October 1, 2021

• Session 3: Opportunities for Targeted Therapies and Immunotherapies
• Session 4: Trial Designs of the Future: Challenges and Opportunities

THURSDAY, SEPTEMBER 30, 2021

Session 1: Where Are We Now with DLBCL Therapy?
Moderator: Sonali M. Smith, University of Chicago, Chicago, Illinois
10-11:25 a.m.

Current landscape of frontline DLBCL therapy
Ranjana H. Advani, Stanford Cancer Institute, Stanford, California

R2-CHOP vs. R-CHOP: Is the verdict in?
Grzegorz S. Nowakowski, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

Panel Discussion
Jeremy S. Abramson, Massachusetts General Hospital, Boston, Massachusetts
Ranjana H. Advani
Brad S. Kahl, Washington University in St. Louis, St. Louis, Missouri
Grzegorz S. Nowakowski
Judith Trotman, University of Sydney, Sydney, NSW, Australia
Wyndham Wilson, National Cancer Institute, Bethesda, Maryland

Break
11:25-11:40 a.m.

Session 2: DLBCL Heterogeneity: Beyond Cell of Origin
Moderator: Ari M. Melnick, Weill Cornell Medical College, New York, New York
11:40 a.m.-1:05 p.m.

Title to be announced
Ash A. Alizadeh, Stanford University, Stanford, California

Heterogeneity in tumor genetics
Louis M. Staudt, National Cancer Institute, Bethesda, Maryland

Panel Discussion
Ash A. Alizadeh
Daniel Hodson, University of Cambridge, Cambridge, United Kingdom
Georg Lenz, University of Münster, Münster, Germany
David W. Scott, BC Cancer, Vancouver, BC, Canada
Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, Massachusetts
Louis M. Staudt

FRIDAY, OCTOBER 1, 2021

Session 3: Opportunities for Targeted Therapies and Immunotherapies
Moderator: Louis M. Staudt, National Cancer Institute, Bethesda, Maryland
10-11:30 a.m.

Title to be announced
Georg Lenz, University of Münster, Münster, Germany

Naked and armed antibodies
Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, New York

Immunotherapy for DLBCL
Stephen M. Ansell, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

Panel Discussion
Stephen M. Ansell
Martin Hutchings, Copenhagen University Hospital, Copenhagen, Denmark
Georg Lenz
Marcela V. Maus, Massachusetts General Hospital, Boston, Massachusetts
Gilles Salles
Jason Westin, The University of Texas MD Anderson Cancer Center, Houston, Texas

Break
11:30-11:45 a.m.

Session 4: Trial Designs of the Future: Challenges and Opportunities
Moderator: Wyndham H. Wilson,National Cancer Institute, Bethesda, Maryland
11:45 a.m.-1:15 p.m.

Title to be announced
Thomas E. Witzig, Mayo Clinic, Rochester, Minnesota

Novel trial designs for aggressive lymphomas
Mark Roschewski, National Cancer Institute, Bethesda, Maryland

Approaches for personalized medicine in lymphoma through liquid biopsies
David M. Kurtz, Stanford University, Stanford, California

Panel Discussion
Sandra J. Horning, Stanford University School of Medicine, Stanford, California
David M. Kurtz
Mark Roschewski
Laurie Sehn, BC Cancer, Vancouver, BC, Canada
Wyndham H. Wilson
Thomas E. Witzig

Meeting Summary and Closing Remarks
1:15-1:30 p.m.

Louis M. Staudt, National Cancer Institute, Bethesda, Maryland